Also listed under Lung Diseases

ClinicalTrials.gov term: Lung Neoplasms

Disease landscape

Lung Cancer clinical trials

Get alerts when Lung Cancer trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-20

What changed in the last 30 days

315 trials changed in the last 30 days: 6 stopped, 112 with notable changes, 197 with minor changes only.

  1. Stopped

    SUPPRESS-NSCLC · Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

    Trial terminated

    Also in this update: Primary completion date changed from estimate of Dec 1, 2026 to Jan 6, 2026; Final enrollment: 52 participants (planned 68)

    Centre hospitalier de l'Université de Montréal (CHUM)Phase 2 NCT04405401 Registry history of NCT04405401 on ClinicalTrials.gov (opens the registry)

  2. Notable

    LIMITLESS · Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

    Primary completion pushed from Jun 1, 2027 to Jun 1, 2031

    Also in this update: Enrollment increased: 30 → 96 participants; Study completion pushed from Dec 1, 2027 to Dec 1, 2031

    InSightecPhase 3 NCT05317858 Registry history of NCT05317858 on ClinicalTrials.gov (opens the registry)

  3. Notable

    BL-B01D1 in Combination With Osimertinib Mesylate Tablets · Locally Advanced or Metastatic Non-small Cell Lung Cancer

    Primary and study completion pushed from Aug 2026 to Jun 2027

    Also in this update: Enrollment closed, study ongoing; Final enrollment: 76 participants (planned 40)

    Sichuan Baili Pharmaceutical Co., Ltd.Phase 2 NCT06498986 Registry history of NCT06498986 on ClinicalTrials.gov (opens the registry)

  4. Notable

    Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment · Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

    Primary completion pushed from Dec 2031 to Nov 2036

    Also in this update: Trial sites expanded: 53 → 65 locations

    AbbViePhase 2/3 NCT07005102 Registry history of NCT07005102 on ClinicalTrials.gov (opens the registry)

  5. Notable

    Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

    Primary completion pushed from Dec 31, 2028 to Dec 31, 2032

    Also in this update: Study completion pushed from Mar 1, 2032 to Mar 1, 2036; and 1 more change in the last 30 days

    Alliance for Clinical Trials in OncologyPhase 2 NCT07293247 Registry history of NCT07293247 on ClinicalTrials.gov (opens the registry)

  6. Notable

    I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance · Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

    Primary completion pushed from Sep 30, 2026 to Jul 20, 2027

    Also in this update: Study completion pushed from Dec 30, 2026 to Feb 20, 2028

    Daiichi SankyoPhase 1/2 NCT06362252 Registry history of NCT06362252 on ClinicalTrials.gov (opens the registry)

  7. Notable

    Pegasus 2 · Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy

    Primary completion pushed from Jan 31, 2029 to Jan 2030

    Also in this update: Recruitment opened; Study completion pushed from May 15, 2029 to Jan 2030

    University Hospital, BrestPhase 3 NCT07289646 Registry history of NCT07289646 on ClinicalTrials.gov (opens the registry)

Show 197 trials with minor changes only
  1. Minor

    LIVIGNO-4 · Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy · Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Enrollment closed, study ongoing

    Also in this update: Final enrollment: 167 participants (planned 840)

    AbbViePhase 2/3 NCT06236438 Registry history of NCT06236438 on ClinicalTrials.gov (opens the registry)

  2. Minor

    TROPION-Lung15 · Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy · EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Enrollment closed, study ongoing

    Also in this update: Primary completion pushed from Sep 30, 2026 to Jan 11, 2027; Trial sites reduced: 303 → 211 locations

    AstraZenecaPhase 3 NCT06417814 Registry history of NCT06417814 on ClinicalTrials.gov (opens the registry)

  3. Minor

    Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy · Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

    Trial completed

    Also in this update: Study completion date changed from estimate of Oct 14, 2026 to Aug 24, 2026

    Merck Sharp & Dohme LLCPhase 3 NCT04956692 Registry history of NCT04956692 on ClinicalTrials.gov (opens the registry)

  4. Minor

    KRASCENDO 3 · Divarasib Compared With Investigator's Choice of Immunotherapy or Observation · Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

    Trial sites expanded: 19 → 46 locations

    Also in this update: Start date changed from estimate of Sep 30, 2026 to Oct 6, 2026

    Hoffmann-La RochePhase 3 NCT07541170 Registry history of NCT07541170 on ClinicalTrials.gov (opens the registry)

  5. Minor

    eVOLVE-Lung02 · Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy · Metastatic Non-small Cell Lung Cancer

    Trial sites reduced: 247 → 231 locations

    Also in this update: Study completion moved earlier from Feb 28, 2029 to Nov 12, 2027; Primary completion date changed from estimate of Feb 28, 2029 to Aug 17, 2026

    AstraZenecaPhase 3 NCT05984277 Registry history of NCT05984277 on ClinicalTrials.gov (opens the registry)

  6. Minor

    BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy · Extensive-Stage Small Cell Lung Cancer (TIGOS)

    Study completion moved earlier from Sep 5, 2031 to Jul 14, 2031

    Also in this update: Primary completion moved earlier from Apr 6, 2028 to Aug 17, 2027

    Bristol-Myers SquibbPhase 3 NCT06646276 Registry history of NCT06646276 on ClinicalTrials.gov (opens the registry)

  7. Minor

    TROPION-Lung12 · Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, · Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

    Study completion moved earlier from Jun 30, 2027 to Mar 31, 2027

    Also in this update: Primary completion date changed from estimate of Jun 30, 2027 to Jul 10, 2026

    AstraZenecaPhase 3 NCT06564844 Registry history of NCT06564844 on ClinicalTrials.gov (opens the registry)

  8. Minor

    MARIPOSA-2 · Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy · Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

    Study completion pushed from Nov 30, 2027 to Jul 3, 2028

    Janssen Research & Development, LLCPhase 3 NCT04988295 Registry history of NCT04988295 on ClinicalTrials.gov (opens the registry)

  9. Minor

    Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment · Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Interventions modified

    Also in this update: Start date changed from estimate of Aug 31, 2026 to Sep 10, 2026

    Bristol-Myers SquibbPhase 2 NCT07680764 Registry history of NCT07680764 on ClinicalTrials.gov (opens the registry)

  10. Minor

    Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

    Study completion moved earlier from Dec 31, 2027 to Jul 31, 2027

    Also in this update: Primary completion date changed from estimate of Aug 31, 2026 to Oct 31, 2025

    Ohio State University Comprehensive Cancer CenterPhase 1 NCT03824327 Registry history of NCT03824327 on ClinicalTrials.gov (opens the registry)

  11. Minor

    Genetic Testing in Screening · Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

    Study completion pushed from Sep 28, 2026 to Sep 21, 2027

    Also in this update: Primary completion date changed from estimate of Sep 28, 2026 to Dec 3, 2025; Final enrollment: 7458 participants (planned 8300)

    National Cancer Institute (NCI)Not applicable NCT02194738 Registry history of NCT02194738 on ClinicalTrials.gov (opens the registry)

  12. Minor
    37 trials marked Unknown by the registry's verification sweep
    1. Minor

      Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study

      Registry marked status Unknown (sponsor has not verified the record since Dec 2023); last known: Recruiting

      Ningbo Medical Center Lihuili HospitalNot applicable NCT06188650 Registry history of NCT06188650 on ClinicalTrials.gov (opens the registry)

      Changed

    2. Minor

      Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

      Registry marked status Unknown (sponsor has not verified the record since Sep 2023); last known: Not Yet Recruiting

      Degan LuPhase 3 NCT06048315 Registry history of NCT06048315 on ClinicalTrials.gov (opens the registry)

      Changed

    3. Minor

      Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

      Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNot specified NCT06653478 Registry history of NCT06653478 on ClinicalTrials.gov (opens the registry)

      Changed

    4. Minor

      Advance Care Planning Impact on the Consistency · Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting

      National Taiwan University HospitalNot applicable NCT06616909 Registry history of NCT06616909 on ClinicalTrials.gov (opens the registry)

      Changed

    Registry verification sweep

    Changed

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-10-19 NCT07879768 Acupuncture and Laser Acupuncture for Advanced Non-Small Cell Lung Cancer China Medical University, Taiwan new
2026-10-15 NCT07875920 Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation Neowise Biotechnology new Phase 1
2026-10-15 NCT07875465 Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid… Bing Xia new Phase 2
2026-10-14 NCT07873450 SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET Full-Life Technologies UK Limited new Phase 1/2
2026-10-08 NCT07864584 Study Using a Drug-device Combination Product to Determine Safety, Tolerability and… Nob Hill Therapeutics, Inc. new Phase 1/2
2026-10-07 NCT07864207 Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With… IDP Discovery Pharma S.L. new Phase 1/2
2026-10-06 NCT07860359 Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking… Hôpital Cantonal de Fribourg new
2026-10-06 NCT07861282 Impact of a Telerehabilitation-based Therapeutic Exercise Program on Postoperative… University of Seville new
2026-10-05 NCT07858253 CLEAR-Lung III: Circulating Tumor DNA-Guided Consolidation Chemotherapy and Immunotherapy Anusha Chidharla, MD new Phase 2
2026-10-01 NCT07853443 Symptoms, Physical Function, and Recovery in Patients Receiving Lung Cancer Treatment… Aerospace Center Hospital new

Active trials by phase

Early Phase 1
43
Phase 1
516
Phase 1/2
402
Phase 2
1,047
Phase 2/3
56
Phase 3
375
Phase 4
44
Not charted: 1,497 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Top sponsors by active trials in this area

Get alerts when Lung Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials